Surmounting the Insurmountable: Obstacles in Drug Discovery and Development - Real World Case Studies
Monday April 23, 2018
9:30 am
-
12:00 pm
Eastern Time (ET)
Room 16A
BEH
DCP
DDD
DMDD
TCP
Chair :
Kan He
Biotranex
Paul Hollenberg
University of Michigan
During the drug discovery and development process in the real world, expert scientists frequently encounter an unexpected obstacle that seems insurmountable. Serious issues with efficacy, toxicity, and pharmacokinetics may unexpectedly threaten the successful development of the whole project. How do experienced scientists deal with such issues? Critical thinking and problem solving are essential for success. This session features recognized experts in drug discovery and development and their fascinating and challenging stories. What went fatally wrong with a particular drug? How was the problem solved?
Speakers
Margaret Bradbury
- Prana Biotech
Challenges and Solutions in the Approval of Austedo, the First Deuterium-Substituted Small Molecule
Francis Lee
- Angex Pharmaceutical Inc.
Discovery and Development Challenges of Dasatinib for the Treatment of Chronic Myelogenous Leukemia and Beyond
Sandeep Dutta
- Amgen
Modeling and Simulation that Resulted in the Progression of Evolucumab
Francis Wolenski
- Takeda Pharmaceuticals International Co.
Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
Paul Hollenberg
- University of Michigan